⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALLO News
Allogene Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Announces Planned CEO Succession
globenewswire.com
ALLO
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
globenewswire.com
ALLO
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
globenewswire.com
ALLO
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
globenewswire.com
ALLO
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight
globenewswire.com
MRK
IPHA
VERU
KURA
INCY
AMGN
PFE
GILD
REGN
AZN
CRSP
BIIB
NTRA
ALLO
KYMR
ADCT
IMUX
CELC
ONON
ABBV
TDOC
BMY
IMVT
GNTX
IMPP
AUTL
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
globenewswire.com
ALLO
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
globenewswire.com
ALLO
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
globenewswire.com
ALLO